BrainStorm provides review of recent accomplishments for shareholders, investors

BrainStorm Cell Therapeutics Inc. (BCLI.PK or BCLI.QB formerly BCLI.OB), a leading developer of adult stem cell technologies and therapeutics, today provided a review of recent accomplishments for shareholders and investors.

Since the beginning of 2011, BrainStorm has made significant progress towards achieving its goal of enrolling patients with amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's Disease, in a Phase I/II clinical trial for BrainStorm's autologous adult stem cell therapy (NurOwn™). BrainStorm anticipates that it will be able to complete patient enrollment and begin the Phase I/II clinical trial during the first half of 2011 at the Hadassah Medical Center.

While the Company is current on all its filings and therefore eligible to be quoted on the Over-the-Counter Bulletin Board ("OTCBB"), due to issues related to the market makers that quote on the OTCBB, the Company, together with hundreds of other companies, is now being quoted on the Pink Sheets and on the OTC.QB. The Company did find a market maker that is willing to file the relevant filings required in order for the Company to be approved by the Financial Industry Regulatory Authority ("FINRA") and reinstated for trade on the OTCBB. Until such forms are filed and approved by FINRA, the Company is being traded on the Pink Sheets at BCLI.PK. Once approved by FINRA, the Company will make an announcement.

The confusion caused by the above mentioned matter has potentially affected the exposure of the Company's most recent press releases detailing its recent achievements. Therefore for those shareholders that follow the Company on stock quote providers, such as Yahoo and Google Finance, which did not reflect our listing change, below is a summary of BrainStorm's achievements during the first three months of 2011:

March 2011

• The second-longest serving White House Chief of Staff, Andrew H. Card, Jr., who was appointed in the presidential administration of George W. Bush, joined the Company's Business Advisory Board. The appointment of Mr. Card adds to the list of prominent members of the Company's Business Advisory Board, including: Dr. Jacob Frenkel, Chairman of JPMorgan Chase International and a member of the JPMorgan Chase (NYSE: JPM) Executive Committee and its International Council; Harvey Krueger, Vice Chairman of Barclays Capital and Chairman Emeritus of Lehman Brothers, Inc.; and Rasheda Ali, author and daughter of former three-times World Heavyweight Champion Muhammad Ali who suffers from Parkinson's disease.

February 2011

• BrainStorm entered into securities purchase agreements with certain institutional and other investors in connection with a private placement financing in reliance upon Regulation S. This transaction closed on February 28, 2011, and the Company received gross proceeds of approximately $3.6 million. The Company also issued warrants to the investors in the financing, and, if exercised in full, would bring in an additional $8.2 million in cash to the Company.
• BrainStorm was granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the Company's NurOwn™ autologous adult stem cell product candidate for the treatment of ALS. This designation affords the Company seven years of marketing exclusivity for NurOwn™ upon regulatory approval, as well as the opportunity to apply for grant funding from the U.S. government to defray costs of clinical trial expenses, tax credits for clinical research expenses and potential exemption from the FDA's application user fee.
• Preclinical results published in Stem Cell Reviews and Reports demonstrated that BrainStorm's NurOwn™ stem cell technology shows promise for treating sciatic nerve injury. Intramuscular transplantation of autologous, astrocyte-like cells that produce and secrete neurotrophic factors (NTFs), representing the company's NurOwn™ technology platform, preserved motor function, significantly inhibited the degeneration of the neuromuscular junctions (NMJs), and preserved the myelinated motor axons in an animal sciatic nerve injury model.

January 2011

• BrainStorm appointed a highly experienced drug developer, Adrian Harel, Ph.D., as the Company's Chief Operating Officer and Acting Chief Executive Officer. Dr. Harel brings to the Company a remarkable record of professional achievement and experience in drug development and manufacturing in addition to building and managing highly successful biotechnology companies.

"We are very excited about the opportunities ahead for BrainStorm, as we are poised to enter Phase I/II clinical development with our NurOwn™ product candidate, which is designed to harness the patient's own regenerative mechanisms to treat ALS and other neurodegenerative diseases," said Chaim Lebovits, President of BrainStorm. "As evidenced by our recent accomplishments, we now have the right people, resources, and strategy in place to leverage our NurOwn™ platform and we look forward to reporting to you on our progress with validation of sterility tests requested by the Israeli Ministry of Health (MOH) and the screening of patients for the trial."